Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIGENERA 2.0: G-CSF and MCE in AMI
NCT02502747Phase 2Withdrawn
- Sponsor
- Università Cattolica del Sacro Cuore
- Start
- Jan 2020
- Primary completion
- Oct 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myocardial infarction (MI) comparing G-CSF + MCE with Placebo + MCE (2 arms). Primary endpoint: Left ventricular ejection fraction at 6 months. Planned start Jan 2020; status: withdrawn.
02
Drugs
lenograstim
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT02502747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502747.